Should we be giving adjuvant nivolumab to all eligible esophageal/GEJ cancer, irrespective of the PD-L1 status of the tumor?  

The FDA approval is regardless of PD-L1 expression. We did not see tumor cell PD-L1 (TPS) enriching for DFS benefit. In a post-hoc exploratory analysis published in the supplementary appendix (S2) of NEJM publication, we evaluated DFS in patients with PD-L1 combined positive score (CPS) >5 compar...

For many years, a major whole in the arsenal for treatment of esophageal and gastroesophageal junctional cancer was the lack of evidence for adjuvant therapy following neoadjuvant chemoradiation and esophagectomy. At GI Oncology tumor boards, we’d frequently hear challenging cases of esophagea...

Yes, the CM 577 trial showed benefit across subgroups by tumor PDL1 status (tumor PDL1 expression < 1% or >= 1%). Thus, I would not use PDL1 status in the decision making for adjuvant nivolumab. Moreover, if PDL1 status is to be checked in esophageal and GE jxn cancer, CPS score (rather than t...